Evan David Seigerman
Stock Analyst at BMO Capital
(3.33)
# 1,043
Out of 5,130 analysts
54
Total ratings
48.94%
Success rate
5.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $110.53 | +17.62% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $796.55 | +6.71% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $326.10 | +14.08% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $58.81 | -21.78% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $8.03 | +36.99% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $220.08 | +9.05% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $17.92 | +45.09% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $26.78 | +4.56% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $12.07 | -17.15% | 1 | May 5, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $70 → $112 | $78.14 | +43.33% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $68.61 | +45.75% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.48 | +41.29% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.71 | -47.46% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,063.56 | -62.77% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $110.53
Upside: +17.62%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $796.55
Upside: +6.71%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $326.10
Upside: +14.08%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $58.81
Upside: -21.78%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $8.03
Upside: +36.99%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $220.08
Upside: +9.05%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $17.92
Upside: +45.09%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $26.78
Upside: +4.56%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $12.07
Upside: -17.15%
Disc Medicine
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $78.14
Upside: +43.33%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $68.61
Upside: +45.75%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.48
Upside: +41.29%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.71
Upside: -47.46%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,063.56
Upside: -62.77%